Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret them. Tarsus is a commercial-stage biopharmaceutical company focused on therapeutics starting with eye care, led by XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis and a lotilaner-based pipeline that includes TP-04 and TP-05.
Through this page, users can access Tarsus’ current and historical filings, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe the company’s business, risk factors, financial statements, and discussion of results. Current reports on Form 8-K provide details on material events such as quarterly financial results, annual meeting outcomes, and other significant corporate developments. For example, recent 8-K filings reference press releases that set forth Tarsus’ results of operations for specific quarters and describe shareholder voting results at the annual meeting.
Investors can also review proxy statements referenced in 8-K filings to understand proposals submitted to stockholders, including director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm. In addition, Form 4 insider transaction reports, when available, can be used to track purchases and sales of TARS shares by directors, officers, and other insiders.
Stock Titan’s AI features summarize lengthy filings, highlight key sections related to revenue dependence on XDEMVY, pipeline development, capital needs, and risk factors, and explain technical language in more accessible terms. Real-time updates from EDGAR ensure that new Tarsus filings, from 10-K and 10-Q reports to 8-K current reports and Form 4 insider filings, appear promptly so users can follow changes in the company’s regulatory and financial profile without manually parsing every document.
The Vanguard Group filed an Amendment No. 2 to a Schedule 13G/A reporting 0 shares beneficially owned of Tarsus Pharmaceuticals Inc common stock and 0% of the class. The filing explains an internal realignment that caused certain subsidiaries to report ownership separately and is signed on 03/27/2026.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan sold 2,989 shares of common stock in an open-market transaction at $66.75 per share on March 20, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the sale, he holds 82,791 shares directly. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those shares.
Seshadri Neervannan reported proposed and completed sales of Common Stock of TARS. The filing lists restricted shares vesting on 03/16/2026 (1,093 shares), 03/17/2026 (1,087 shares) and 03/18/2026 (809 shares). The filing also reports open-market sales during the prior three months of 8,366, 3,125, 3,610 and 4,589 shares on 03/04/2026, 03/17/2026, 03/18/2026 and 03/19/2026, respectively, with aggregate proceeds shown per sale.
Tarsus Pharmaceuticals Chief Human Resources Officer Dianne C. Whitfield reported mandated sales of common stock to cover tax withholding obligations tied to restricted stock unit vesting. Over three days, she sold a total of 12,274 shares in open-market transactions at prices between $67 and $69.42 per share. After these sales, she directly held 35,028 shares of common stock. A footnote explains the transactions were "sell to cover" sales required by the company’s tax policy and were not discretionary trades initiated by her.
Tarsus Pharmaceuticals, Inc. reported that its General Counsel, Bryan Wahl, sold a total of 12,440 shares of common stock over three days at prices between $67.00 and $69.42 per share. According to the footnote, these sales were made solely to cover tax withholding obligations tied to the vesting and settlement of restricted stock units and were mandated by the company’s sell-to-cover election, meaning they were not discretionary trades by Wahl. After these transactions, he holds 63,959 shares of Tarsus common stock directly.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan reported mandatory share sales to cover taxes tied to restricted stock vesting. On March 17–19, 2026, he sold 11,324 shares of common stock in open-market transactions at prices between $67.00 and $69.42 per share. A footnote explains these were issuer-required “sell to cover” trades for tax withholding, not discretionary sales. After the transactions, he directly holds 85,780 shares of common stock. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those securities.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported mandated stock sales tied to tax withholding on vested Restricted Stock Units. Over March 17–19, he sold a total of 13,056 shares of common stock in open-market transactions at prices around $67–$69 per share. According to the footnote, these "sell to cover" trades were required by the company to satisfy tax obligations and were not discretionary investment decisions. After these sales, Mottiwala directly holds 61,480 shares of Tarsus Pharmaceuticals common stock.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu reported mandated share sales to cover taxes from vesting restricted stock units. Over March 17–19, she sold a total of 1,144 shares of common stock in open-market transactions, including 390 shares at $67.0000 per share and 379 shares at $68.7100 per share.
According to the disclosure, these “sell to cover” trades were required under the company’s tax withholding election and were not discretionary. After the transactions, Yeu directly held 23,308 common shares, with additional indirect holdings of 6,360 shares through her spouse’s Roth IRA and 12,040 shares through a 401(k) plan.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported selling 6,430 shares of common stock in open‑market transactions over three days. He sold 2,111 shares at $69.42, 2,133 shares at $68.71, and 2,186 shares at $67.00 per share.
According to the disclosure, these sales were mandated "sell to cover" transactions to fund tax withholding obligations from vesting restricted stock units, rather than discretionary trades. After the sales, Farrow directly holds 43,316 Tarsus shares.
Tarsus Pharmaceuticals, Inc. President, CEO and Board Chair Bobak R. Azamian reported selling 34,603 shares of common stock in open-market transactions over three days at prices ranging from $67.00 to $69.42 per share. These sales were executed solely to cover tax withholding obligations tied to the vesting and settlement of restricted stock units under a mandated "sell to cover" arrangement, rather than as discretionary trades.
Following the transactions, he directly holds 33,421 common shares. He also serves as trustee of the Bobak Azamian Living Trust, which holds an additional 857,991 common shares over which he has voting and dispositive power.